FreeMind Group Webinar
Ayal RonenAugust 14th, 2012
Non-Dilutive Funding for Industry-Academic Partnerships
August 21, 2012 FreeMind Group, LLC 2/28
FreeMind Summer SchoolFreeMind Summer School
FreeMind Group, LLC
FreeMind Group, LLC
Join us every Tuesday at Noon EDT for
the weekly FreeMind educational webinar.
Syllabus:1. SBIR/STTR2. Details of a Detailed Budget
3. Joint webinar with the Michael J. Fox Foundation on Parkinson’s and other Neurological disorders4. BARDA – mission and current funding opportunities5. Cancer
6. Medical Devices funding opportunities7. Industry Academic Partnership Programs 8. Biodefense and infectious diseases, NIAID 9. DOD – DARPA, DTRA, US Army, etc.Webinar program is
subject to change
August 21, 2012 FreeMind Group, LLC 3/28
� Est. 1999
� 25 Fulltime Employees
� Academia & Industry Clientele
� Extensive experience in submitting and winning large scale applications
� Over $1.5B in cumulative awards
The Global NonThe Global Non--Dilutive Funding Leader Dilutive Funding Leader
FreeMind Group, LLC
FreeMind Group, LLC
August 21, 2012 FreeMind Group, LLC 4/28
� Identifying most relevant funding opportunities
� Strategize to max. application’s chances
� Manage complex project production processes
� Lead joint application writing
� Supports final contract negotiations
A Tool to Max. Your Funding PotentialA Tool to Max. Your Funding Potential
FreeMind Group, LLC
FreeMind Group, LLC
August 21, 2012 FreeMind Group, LLC 5/28
Industry Industry -- Academic PartnershipsAcademic Partnerships
PartnershipsPartnerships
Commercialization
• Large Pharma
• Entrepreneurs • Tech Transfer• Government
Funding?
August 21, 2012 FreeMind Group, LLC 6/28
VC vs. Non-Dilutive funding
VC vs. Non-Dilutive funding
2010, 2011 Investments in Life Science Companies2010, 2011 Investments in Life Science Companies
Non-dilutive
For Industry
Dilutive
Adapted from the NIH Data Book, and OnBioVc trend analysis 2010, 2011
$50B
$7.5B$5.2B $6.07B
Dilutive
Life Science
companies cannot afford to ignore this pocket of money.
Ask your self:
What are my competitors doing?
August 21, 2012 FreeMind Group, LLC 7/28
Francis Collins, NIH Director
Francis Collins, NIH Director
“Through partnerships that capitalize on our respective strengths, NIH, academia,…and the private sector can take full advantage of the promise of translational science to deliver solutions to the millions of people”
Partnership Programs at the NIHPartnership Programs at the NIH
Francis S. Collins. Reengineering Translational Science: The Time Is Right. Science Translation Medicine. Vol 3 Issue 90 Jul. 2011
Realization that medical benefits of the current revolution in biology clearly cannot be achieved without vigorous and effective translation;
National Center for Advancing Translational Sciences (NCATS) - total FY2012 budget will be $570 million.
“In all of these examples, partnerships with the private sector have been essential for ultimate success.”
August 21, 2012 FreeMind Group, LLC 8/39
NCATSNCATS
National Center for Advancing Translational SciencesNational Center for Advancing Translational Sciences (NCATS)(NCATS)
Main Goals• Overcome translational pipeline barriers.
• Testing pipeline innovations with promising research projects.• Cultivating strong partnerships.• Increasing collaboration with the FDA• Supporting an innovative and collaborative training program.
Some 14 different programs; examples:
• Therapeutics for Rare and Neglected Diseases (TRND) -Speed the development of new drugs for rare and neglected diseases; Deadline: September 28th, 2012!
• Cures Acceleration Network (CAN) - address scientific and
technical challenges that impede transitional research.
CAN will support the following activities:
• Rescuing and Repurposing Drugs
• Tissue Chip for Drug Screening• Identifying and Validating Drug Targets
Established in 2012
2013 Budget request
$639M
August 21, 2012 FreeMind Group, LLC 9/39
NIH, DoDNIH, DoD
Current Partnership Funding OpportunitiesCurrent Partnership Funding Opportunities
• Many more examples • Big Pharma and the FreeMind Group; Industry - Academia,
Industry - Industry collaborations
• FMG and the Seattle Structural Genomics Center for Infectious Disease – Consortium comprised of Seattle Biomed, UW, Emerald BioStructures, and Pacific Northwest National Laboratory - $39.6M
• Not just specific solicitations – also investigator initiated programs
• Collaborations are strongly encouraged on ALL grants.
August 21, 2012 FreeMind Group, LLC 10/39
SBIR/STTRSBIR/STTR
Small Businesses and the AcademiaSmall Businesses and the Academia
The STTR program is intended to:
Stimulate a partnership of ideas and technologies between innovative small businesses and non-profit research institutions. The STTR program assists the small business and research communitiesby commercializing innovative technologies.
Does have it’s core limitations, mainly eligibility as well as percent efforts by the respective parties (Small Business at least 40%, Institution at least 28%).
SBIR/STTR is 2.5% of the budget, STTR – roughly 0.85%
(Parent STTR [R41/R42])PA-12-089
•Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications
August 21, 2012 FreeMind Group, LLC 11/28
Funding OpportunitiesFunding Opportunities
And now, some specific partnership funding opportunities
August 21, 2012 FreeMind Group, LLC 12/28
NIAID - RO1NIAID - RO1
Partnerships for Development of Therapeutics and Diagnostics Partnerships for Development of Therapeutics and Diagnostics for Biodefense (RFAfor Biodefense (RFA--AIAI--1010--003)003)
Funding: up to $3.75M over 5 years in Direct costs ($750,000 per year).
In addition, applicants may request up to a total of $280,000 for major equipment (1st year)
Scope:• To support preclinical research that will advance the
development and/or production of lead biodefense countermeasures (vaccines, vaccine technologies, adjuvants, therapeutics, immunotherapeutics, and medical diagnostics) specific for NIAID Category A, B, or C priority agents. •Applications must present a Product Development Strategy and demonstrate substantive investment by at least one industrial participant.
Deadlines:
Letter of intent:
April 24, 2012
Full application:
May 24, 2012
Start Date: April 2013
Deadlines:
Letter of intent:
April 24, 2012
Full application:
May 24, 2012
Start Date: April 2013
August 21, 2012 FreeMind Group, LLC 13/28
NIAID -R21/R33
NIAID -R21/R33
Partnerships for Interventions to Treat Chronic, Persistent Partnerships for Interventions to Treat Chronic, Persistent and Latent Infections (RFAand Latent Infections (RFA--AIAI--1212--020)020)
Funding: For the R21 phase, direct costs can be requested up to $275,000 over 2 years. For the R33 phase, direct costs can be requested up to $900,000 over 3 years ($280,000 per year).
Scope:
• This initiative by NIAID seeks to stimulate basic and early stage translational research focused on development of novel intervention strategies to clear persistent, chronic or latent infectious agents from the host.
• Responsive applications will define and address a therapeutic need specific to a targeted pathogen
• Milestones!
Deadlines:
Full application: June 13, 2012
Start Date: April 2013
Deadlines:
Full application: June 13, 2012
Start Date: April 2013
August 21, 2012 FreeMind Group, LLC 14/28
NIAID - RO1NIAID - RO1
Partnerships for Development of Vaccine Technologies Partnerships for Development of Vaccine Technologies (RFA(RFA--AIAI--1212--014)014)
Funding: up to $3.75M over 5 years in Direct costs ($750,000 per year).
In addition, applicants may request up to a total of $280,000 for major equipment (1st year)
Scope:• To support preclinical development of candidate
technologies that would improve vaccine effectiveness and/or simplify vaccine delivery during a natural outbreak
or following intentional release of an infectious agent. •Projects that would benefit production, delivery, stability and/or efficacy of non-biodefense-related vaccines are responsive provided that the targeted technology would be applicable to biodefense-related products.
•Applications must include a Product Development Strategy and demonstrate substantive investment by at least one industrial participant
Deadlines:
Full application: June 26, 2012
Start Date: April 2013
Deadlines:
Full application: June 26, 2012
Start Date: April 2013
August 21, 2012 FreeMind Group, LLC 15/28
NCINCI
AcademicAcademic--Industrial Partnerships for Translation of in vivo Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01)(PARImaging Systems for Cancer Investigations (R01)(PAR--1010--169 )169 )
Funding: $500,000 Direct cost/yr for up to 5 yrs.
Scope:• Research partnerships formed by academic and industrial
investigators to accelerate the translation of either animal or human in vivo imaging, image guided, and/or spectroscopic systems and methods designed to solve targeted cancer problems for cancer research, clinical trials, and/or clinical
practice. • Inter-disciplinary, multi-institutional research team to work in a strategic alliance to implement a coherent strategy to develop and translate the proposed system or methods with potential for significant impact on preclinical, single, or
multisite clinical studies. • Supports clinical trials that emphasize optimization and validation of the performance of imaging systems, including devices, agents and/or methods.
• Does not support commercial production.
Deadline:Oct 5th, 2012
Deadline:Oct 5th, 2012
August 21, 2012 FreeMind Group, LLC 16/28
NCINCI
ImageImage--Guided Cancer Interventions (STTR [R41/R42])Guided Cancer Interventions (STTR [R41/R42])(PA(PA--1010--080)080)
Funding: $150,000 Direct cost for Phase I (2yr), $1M Direct cost for Phase II (3yr).
Scope:
•Propose the development and clinical validation of systems for image-guided interventions (IGI) for cancer.• Provide support for: the development, optimization and validation of fully integrated cancer imaging, monitoring, and therapy systems; the development of multiple prototype integrated IGI systems as required for multisite clinical evaluations; in order to reach the research goals.
Deadline:Dec 5th, 2012
Deadline:Dec 5th, 2012
August 21, 2012 FreeMind Group, LLC 17/28
NCINCI
Quantitative Imaging for Evaluation of Responses to Cancer Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01) (PARTherapies (U01) (PAR--1111--150)150)
Funding: $500,000 Direct cost/yr for up to 5 yrs.
Scope:
• To promote research on quantitative imaging of tumor response to cancer therapies in clinical trial settings.
• Development of quantitative imaging methods, protocols and software solutions and their application in clinical therapy trials. Focus on imaging-derived quantitative measurements of responses to drugs and/or radiation therapy, and/or image-guided interventions.
• Multidisciplinary efforts - involvement of industrial partners is not required, but is strongly encouraged.
Deadline:Oct 5th, 2012
Deadline:Oct 5th, 2012
August 21, 2012 FreeMind Group, LLC 18/34
NIBIBNIBIB
Bioengineering Research Partnerships (BRP)[R01] Bioengineering Research Partnerships (BRP)[R01] (PAR(PAR--1010--234 )234 )
Funding: No more than $2M/year. Up to 5 years
Scope:
• BRPs for basic, applied, and translational multi-disciplinary research that addresses important biological, clinical or biomedical research problems.
• Integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. Design-directed, developmental, discovery-driven, or hypothesis-driven research
• Some BRP projects may propose research that could lead to a novel device as a product
Deadline:Oct 5th, 2012
Deadline:Oct 5th, 2012
August 21, 2012 FreeMind Group, LLC 19/28
NIAID -R21/R33
NIAID -R21/R33
NIDCD Research Grants for Translating Basic Research into NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01)(PARClinical Tools (R01)(PAR--1111--003)003)
Funding: Not capped, should reflect the scope of the work. Preapproval for over $500K/year.
Scope:• Translate basic research findings into clinical tools
for better human health; in areas of hearing, balance, smell, taste, voice, speech and language.
• To provide a new avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects.
• To encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders.
• Multi-institutional, multi-disciplinary, and academic-industrial collaborations studies are encouraged.
Deadline:
Due date:
Feb 22, 2013
Deadline:
Due date:
Feb 22, 2013
August 21, 2012 FreeMind Group, LLC 20/28
NIMH, NIAAA, NIDA
NIMH, NIAAA, NIDA
National Cooperative Drug Discovery/ Development Groups (NCDDG) National Cooperative Drug Discovery/ Development Groups (NCDDG) for the for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U19) (Treatment of Mental Disorders, Drug or Alcohol Addiction (U19) (PARPAR--1111--207)207)
Funding: Not capped, should reflect the scope of the work. Preapproval for over $500K/year.
Scope:•To create multidisciplinary research groups or partnerships for the discovery of pharmacological agents to treat and to study mental illness, drug or alcohol addiction. •To advance the discovery, preclinical development, and proof of concept testing of new, rationally based candidate medications to treat mental disorders or drug or alcohol addiction, and to develop novel ligands as tools to further characterize existing or to validate new drug targets. •Partnerships between academia and industry are strongly encouraged.
Deadline:
Due date:
Oct 22, 2012
Deadline:
Due date:
Oct 22, 2012
August 21, 2012 FreeMind Group, LLC 21/28
Key ChallengesKey Challenges
Overcoming the ChallengesOvercoming the Challenges
1. Different mechanisms with varying requirements
2. Writing and assembling the application
3. Plan for Multi PI
3. Responsive vs. Competitive; leadership, significance, innovative, approach, and environment.
August 21, 2012 FreeMind Group, LLC 22/33
Risk Assessment
Risk Assessment
NIH Review ProcessNIH Review Process
Risk
Strength
Responsive vs. Competitive
August 21, 2012 FreeMind Group, LLC 23/28
Key IssuesKey Issues
Maximizing Your ChancesMaximizing Your Chances
• Know the interests of the Agency
• Focus your project application
• Ask for what is necessary
• Present a complete project
• Leverage on research collaborations
Systematic Approach
August 21, 2012 FreeMind Group, LLC 24/28
Key IssuesKey Issues
Maximizing Your ChancesMaximizing Your Chances
• Different “pockets of money”
• Different size of award/success rates
• Some projects will not have the right target
• Conduct a thorough strategic assessment
Target the Right Mechanism
August 21, 2012 FreeMind Group, LLC 25/28
The Professional
Team
The Professional
Team
FreeMindFreeMind’’s NIH Teams NIH Team
� 25 full time employees
�Analysts
�Managers/Writers
� Dr. Merav Geva, FreeMind’s Director of the
Professional Department & Chief Analyst
August 21, 2012 FreeMind Group, LLC 26/28
Strategic
Assessment
Strategic
Assessment
FMG Professional ProcessFMG Professional Process
August 21, 2012 FreeMind Group, LLC 27/28
Specific ProjectSpecific Project
FMG Professional ProcessFMG Professional Process
August 21, 2012 FreeMind Group, LLC 28/28
Contact Us!Contact Us!
Thank you!Thank you!
Ayal Ronen
Vice [email protected]
(617) 648 0280
www.freemindconsultants.com
Ayal Ronen Ayal Ronen
Vice [email protected]
(617) 648 0280
www.freemindconsultants.com